PPAR-γ activation as an anti-inflammatory therapy for respiratory virus infections

Viral Immunology

Volumn 23, Issue 4, 2010, Pages 343-352

  Bassaganya Riera, Josep ^a   Song, Rong ^a   Roberts, Paul C ^b   Hontecillas, Raquel ^a  

^a VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

^b VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

cytokines; inflammation; influenza virus; peroxisome proliferator activated receptor

Indexed keywords

CELECOXIB; CIGLITAZONE; CYTOKINE; GEMFIBROZIL; MESALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; TROGLITAZONE;

ANTIINFLAMMATORY ACTIVITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; EPITHELIUM CELL; HUMAN; IMMUNOCOMPETENT CELL; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; LUNG ALVEOLUS MACROPHAGE; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; REVIEW; VIRAL RESPIRATORY TRACT INFECTION; VIRUS PATHOGENESIS; VIRUS PNEUMONIA;

ANTI-INFLAMMATORY AGENTS; CHRONIC DISEASE; DOWN-REGULATION; HUMANS; INFLUENZA, HUMAN; PPAR GAMMA; RESPIRATORY TRACT INFECTIONS;

ORTHOMYXOVIRIDAE;

EID: 77955860573     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2010.0016     Document Type: Review

References (121)

1. Hippenstiel S, Opitz B, Schmeck B, and Suttorp N: Lung epithelium as a sentinel and effector system in pneumonia- molecular mechanisms of pathogen recognition and signal transduction. Respir Res 2006;7:97.
2. Rothberg MB, Haessler SD, and Brown RB: Complications of viral influenza. Am J Med 2008;121:258-264.
3. Chen J, and Deng YM: Influenza virus antigenic variation, host antibody production and new approach to control epidemics. Virol J 2009;6:30.
4. Cohen J, and Enserink M: After delays, WHO agrees: the 2009 pandemia has begun. Science 2009;324:1496-1497.
5. Enserink M, Cohen J: Virus of the year. The novel H1N1 influenza Science 2009;326:1607.
6. Quigley E: Influenza therapies: vaccines and antiviral drugs. Drug Discov Today 2006;11:478-480.
7. De Jong MD, Simmons CP, Thanh TT, et al.: Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006;12:1203-1207.
8. Fedson DS: Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006;43: 199-205.
9. Fedson DS: Statin protection against influenza and COPD mortality. Chest 2007;132:1406; author reply 1406-1407.
10. Butler D: Cheaper approaches to flue divide researchers. Nature 2007;448:976-977.
11. Fedson DS: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Resp Viruses 2009;3:129-142.
12. Clark I, and Alleva L: Invited commentary on David Fedson's article. Influenza Other Resp Viruses 2009;3: 199-201.
13. Fedson DS: Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis 2008;8:571-576.
14. Jain S, Kamimoto L, Bramley AM, et al.: Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009;361:1935-1944.
15. Ahmed R, Oldstone MB, and Palese P: Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat Immunol 20078:1188-1193.
16. Kash JC, Tumpey TM, Proll SC, et al.: Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 2006;443:578-581.
17. Gill JR, Sheng ZM, Ely SF, et al.: Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med 2010;134:235-243.
18. Salomon R, Hoffmann E, and Webster RG: Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci USA 2007;104: 12479-12481.
19. Szretter KJ, Gangappa S, Lu X, et al.: Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol 2007;81:2736-2744.
20. Almog Y, Novack V, Eisinger M, et al.: The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 2007;35:372-378.
21. Kruger P, Fitzsimmons K, Cook D, et al.: Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2006;32:75-79.
22. Kwong JC, Li P, and Redelmeier DA: Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS One 2009;4:e8087.
23. Budd A, Alleva L, Alsharifi M, et al.: Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother 2007;51:2965-2968.
24. Aldridge JR Jr, Moseley CE, Boltz DA, et al.: TNF/iNOSproducing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci USA 2009;106:5306-5311.
25. Arnold R, and Konig W: Peroxisome-proliferator-activated receptor-gamma agonists inhibit the release of proinflammatory cytokines from RSV-infected epithelial cells. Virology 2006;346:427-439.
26. Arnold R, Neumann M, and Konig W: Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells. Immunology 2007;121:71-81.
27. Arnold R, and Konig W: Peroxisome proliferator-activated receptor-gamma agonists inhibit the replication of respiratory syncytial virus (RSV) in human lung epithelial cells. Virology 2006;350:335-346.
28. Zheng BJ, Chan KW, Lin YP, et al.: Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008;105:8091-8096.
29. Rousseaux C, Lefebvre B, Dubuquoy L, et al.: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med 2005;201:1205-1215.
30. Mangelsdorf DJ, Thummel C, Beato M, et al.: The nuclear receptor superfamily: the second decade. Cell 1995;83: 835-839.
31. Escher P, Braissant O, Basu-Modak S, et al.: Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001;142:4195-4202.
32. Bassaganya-Riera J, Guri A, King J, and Hontecillas R: Peroxisome proliferator-activated receptors: The nutritionally controlled molecular networks that integrate inflammation, immunity and metabolism. Curr Nutr Food Sci 2005;1:179-187.
33. Guri AJ, Hontecillas R, and Bassaganya-Riera J: Peroxisome proliferator-activated receptors: Bridging metabolic syndrome with molecular nutrition. Clin Nutr 2006;25: 871-885.
34. Graves RA, Tontonoz P, and Spiegelman BM: Analysis of a tissue-specific enhancer: ARF6 regulates adipogenic gene expression. Mol Cell Biol 1992;12:3313.
35. Tontonoz P, Hu E, Graves RA, et al.: mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994;8:1224-1234.
36. Lehmann JM, Moore LB, Smith-Oliver TA, et al.: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor gamma (PPAR gamma). J Biol Chem 1995;270:12953-12956.
37. Katayama K, Wada K, Nakajima A, et al.: A novel PPARgamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 2003;124:1315-1324.
38. Lytle C, Tod TJ, Vo KT, et al.: The peroxisome proliferatoractivated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Inflamm Bowel Dis 2005;11: 231-243.
39. Wohlfert EA, Nichols FC, Nevius E, and Clark RB: Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J Immunol 2007;178:4129-4135.
40. Bassaganya-Riera J, Reynolds K, Martino-Catt S, et al.: Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 2004;127:777-791.
41. Lewis JD, Lichtenstein GR, Deren JJ, et al.: Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 2008;134:688-695.
42. Mokdad AH, Bowman BA, Ford ES, et al.: The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286:1195-1200.
43. Desvergne B, and Wahli W: Peroxisome proliferatoractivated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649-688.
44. Nesto RW, Bell D, Bonow RO, et al.: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003;108:2941-2948.
45. Huang JT, Welch JS, Ricote M, et al.: Interleukin-4- dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999;400:378-382.
46. Zhou M, Wu R, Dong W, et al.: Endotoxin downregulates peroxisome proliferator-activated receptor-gamma via the increase in TNF-alpha release. Am J Physiol Regul Integr Comp Physiol 2008;294:R84-R92.
47. Gearing KL, Gottlicher M, Teboul M, et al.: Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci USA 1993;90:1440-1444.
48. Tontonoz P, and Spiegelman BM: Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008;77: 289-312.
49. Ricote M, and Glass CK: PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 2007; 1771:926-935.
50. Straus DS, and Glass CK: Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007;28:551-558.
51. Pascual G, Fong AL, Ogawa S, et al.: A SUMOylationdependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005;437: 759-763.
52. Jennewein C, Kuhn AM, Schmidt MV, et al.: Sumoylation of peroxisome proliferator-activated receptor gamma by apoptotic cells prevents lipopolysaccharide-induced NCoR removal from kappaB binding sites mediating transrepression of proinflammatory cytokines. J Immunol 2008; 181:5646-5652.
53. Diradourian C, Girard J, and Pegorier JP: Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 2005;87:33-38.
54. Becker J, Delayre-Orthez C, Frossard N, and Pons F: Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol 2006;20:429-447.
55. Moore KJ, Fitzgerald ML, and Freeman MW: Peroxisome proliferator- activated receptors in macrophage biology: friend or foe? Curr Opin Lipidol 2001;12:519-527.
56. Szatmari I, Torocsik D, Agostini M, et al.: PPARgamma regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood 2007;110:3271-3280.
57. Smith MR, Standiford TJ, and Reddy RC: PPARs in alveolar macrophage biology. PPAR Res 2007;23812.
58. Kobayashi M, Thomassen MJ, Rambasek T, et al.: An inverse relationship between peroxisome proliferatoractivated receptor gamma and allergic airway inflammation in an allergen challenge model. Ann Allergy Asthma Immunol 2005;95:468-473.
59. Richards DB, Bareille P, Lindo EL, et al.: Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: A randomised controlled trial. Respir Med 2009; 104:668-674.
60. Huang TH, Razmovski-Naumovski V, Kota BP, et al.: The pathophysiological function of peroxisome proliferator-activated receptor-gamma in lung-related diseases. Respir Res 2005;6:102.
61. Burgess HA, Daugherty LE, Thatcher TH, et al.: PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005;288:L1146-1153.
62. Woerly G, Honda K, Loyens M, et al.: Peroxisome proliferator- activated receptors alpha and gamma downregulate allergic inflammation and eosinophil activation. J Exp Med 2003;198:411-421.
63. Trifilieff A, Bench A, Hanley M, et al.: PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. Br J Pharmacol 2003;139: 163-171.
64. McGill J, Heusel JW, and Legge KL: Innate immune control and regulation of influenza virus infections. J Leukoc Biol 2009;86:803-812.
65. Serbina NV, Salazar-Mather TP, Biron CA, et al.: TNF/ iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 2003;19:59-70.
66. Holt PG, Strickland DH, Wikstrom ME, and Jahnsen FL: Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol 2008;8:142-152.
67. Guillot L, Le Goffic R, Bloch S, et al.: Involvement of tolllike receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 2005;280:5571-5580.
68. Chan MC, Cheung Cy, Chui WH, et al.: Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 2005;6:135.
69. Tesfaigzi Y: Roles of apoptosis in airway epithelia. Am J Respir Cell Mol Biol 2006;34:537-547.
70. Zamarin D, Garcia-Sastre A, Xiao X, et al.: Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS Pathog 2005;1:e4.
71. Herold S, Steinmueller M, von Wulffen W, et al.: Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J Exp Med 2008;205:3065-3077.
72. Brydon EW, Smith H, and Sweet C: Influenza A virusinduced apoptosis in bronchiolar epithelial (NCI-H292) cells limits pro-inflammatory cytokine release. J Gen Virol 2003;84:2389-2400.
73. Wang AC, Dai X, Luu B, and Conrad DJ: Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am J Respir Cell Mol Biol 2001;24: 688-693.
74. Perrone LA, Plowden JK, Garcia-Sastre A, et al.: H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog 2008;4:e1000115.
75. Cheung CY, Poon LL, Lau AS, et al.: Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002;360:1831-1837.
76. Kaufmann A, Salentin R, Meyer RG, et al.: Defense against influenza A virus infection: essential role of the chemokine system. Immunobiology 2001;204:603-613.
77. Hui KP, Lee SM, Cheung CY, et al.: Induction of proinflammatory cytokines in primary human macrophages by influenza A virus (H5N1) is selectively regulated by IFN regulatory factor 3 and p38 MAPK. J Immunol 2009;182: 1088-1098.
78. MacLean JA, Xia W, Pinto CE, et al.: Sequestration of inhaled particulate antigens by lung phagocytes. A mechanism for the effective inhibition of pulmonary cellmediated immunity. Am J Pathol 1996;148:657-666.
79. Herold S, W von Wulffen, M Steinmueller, et al.: 2006 Alveolar epithelial cells direct monocyte transepithelial migration upon influenza virus infection: impact of chemokines and adhesion molecules. J Immunol 1996;177: 1817-1824.
80. Thepen T, Van Rooijen N, and Kraal G: Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice. J Exp Med 1989; 170:499-509.
81. Holt PG, Oliver J, Bilyk N, et al.: Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J Exp Med 1993;177:397-407.
82. Morris DG, Huang X, Kaminski N, et al.: Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes Mmp12-dependent emphysema. Nature 2003;422:169-173.
83. Asada K, Sasaki S, Suda T, et al.: Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am J Respir Crit Care Med 2004;169:195-200.
84. Ricote M, Valledor AF, and Glass CK: Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24:230-239.
85. Jakubzick C, Tacke F, Llodra J, et al.: Modulation of dendritic cell trafficking to and from the airways. J Immunol 2006;176:3578-3584.
86. Lin KL, Suzuki Y, Nakano H, et al.: CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. J Immunol 2008;180:2562-2572.
87. Wareing MD, Lyon A, Inglis C, et al.: Chemokine regulation of the inflammatory response to a low-dose influenza infection in CCR2-/- mice. J Leukoc Biol 2007;81:793-801.
88. Reddy RC, Keshamouni VG, Jaigirdar SH, et al.: Deactivation of murine alveolar macrophages by peroxisome proliferator- activated receptor-gamma ligands. Am J Physiol Lung Cell Mol Physiol 2004;286:L613-L619.
89. Bonfield TL, Farver CF, Barna BP, et al.: Peroxisome proliferator- activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar proteinosis. Am J Respir Cell Mol Biol 2003;29:677-682.
90. Malur A, McCoy AJ, Arce S, et al.: Deletion of PPAR gamma in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response. J Immunol 2009;182: 5816-5822.
91. Bonfield TL, Thomassen MJ, Farver CF, et al.: Peroxisome proliferator-activated receptor-gamma regulates the expression of alveolar macrophage macrophage colonystimulating factor. J Immunol 2008;181:235-242.
92. Kintscher U, Goetze S, Wakino S, et al.: Peroxisome proliferator- activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol 2000;401:259-270.
93. Serbina NV, and Pamer EG: Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 2006;7:311-317.
94. Klotz L, Dani I, Edenhofer F, et al.: Peroxisome proliferatoractivated receptor gamma control of dendritic cell function contributes to development of CD4+ T cell anergy. J Immunol 2007;178:2122-2131.
95. Nencioni A, Grunebach F, Zobywlaski A, et al.: Dendritic cell immunogenicity is regulated by peroxisome proliferator- activated receptor gamma. J Immunol 2002;169: 1228-1235.
96. Szatmari I, Gogolak P, Im JS, et al.: Activation of PPARgamma specifies a dendritic cell subtype capable of enhanced induction of iNKT cell expansion. Immunity 2004;21:95-106.
97. Guillonneau C, Mintern JD, Hubert FX, et al.: Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci USA 2009;106:3330-3335.
98. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, et al.: The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000;164:1364-1371.
99. Hontecillas R, and Bassaganya-Riera J: Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. J Immunol 2007;178:2940-2949.
100. Hamada H, Garcia-Hernandez Mde L, Reome JB, et al.: Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol 2009;182:3469-3481.
101. Bender BS, Croghan T, Zhang L, Small PA Jr: Transgenic mice lacking class I major histocompatibility complexrestricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 1992;175:1143-1145.
102. Graham MB and Braciale TJ: Resistance to and recovery from lethal influenza virus infection in B lymphocytedeficient mice. J Exp Med 1997;186:2063-2068.
103. You D, Ripple M, Balakrishna S, et al.: Inchoate CD8+ T cell responses in neonatal mice permit influenza-induced persistent pulmonary dysfunction. J Immunol 2008;181: 3486-3494.
104. Stoll S, Delon J, Brotz TM, and Germain RN: Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science 2002;296:1873-1876.
105. Carding SR, Allan W, McMickle A, and Doherty PC: Activation of cytokine genes in T cells during primary and secondary murine influenza pneumonia. J Exp Med 1993; 177:475-482.
106. Lawrence CW, and Braciale TJ: Activation, differentiation, and migration of naive virus-specific CD8+ T cells during pulmonary influenza virus infection. J Immunol 2004;173: 1209-1218.
107. Roman E, Miller E, Harmsen A, et al.: CD4 effector T cell subsets in the response to influenza: heterogeneity, migration, and function. J Exp Med 2002;196:957-968.
108. Moore KW, de Waal Malefyt R, Coffman RL, and O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
109. Sun J, Madan R, Karp Cl, and Braciale TJ: Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 2009;15:277-284.
110. Klotz L, Hucke S, Thimm D, et al.: Increased antigen crosspresentation but impaired cross-priming after activation of peroxisome proliferator-activated receptor gamma is mediated by up-regulation of B7H1. J Immunol 2009;183: 129-136.
111. Tate MD, Brooks AG, and Reading PC: The role of neutrophils in the upper and lower respiratory tract during influenza virus infection of mice. Respir Res 2008;9:57.
112. Colamussi ML, White MR, Crouch E, and Hartshorn KL: Influenza A virus accelerates neutrophil apoptosis and markedly potentiates apoptotic effects of bacteria. Blood 1999;93:2395-2403.
113. Wareing MD, Shea AL, Inglis CA, et al.: CXCR2 is required for neutrophil recruitment to the lung during influenza virus infection, but is not essential for viral clearance. Viral Immunol 2007;20:369-378.
114. Tate MD, Deng YM, Jones JE, et al.: Neutrophils ameliorate lung injury and the development of severe disease during influenza infection. J Immunol 2009;183:7441-7450.
115. Reddy RC, Narala VR, Keshamouni VG, et al.: Sepsisinduced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor- {gamma}. Blood 2008;112:4250-4258.
116. Kim MS, Sweeney TR, Shigenaga JK, et al.: Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC- 1alpha, and PGC-1beta in liver cells. Metabolism 2007;56: 267-279.
117. Weinberger B, Quizon C, Vetrano AM, et al.: Mechanisms mediating reduced responsiveness of neonatal neutrophils to lipoxin A4. Pediatr Res 2008;64:393-398.
118. Chima RS, Hake PW, Piraino G, et al.: Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock. Crit Care Med 2008;36:2849-2857.
119. Nicholson S, Bonecini-Almeida Mda G, Lapa e Silva JR, et al.: Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med 1996;183:2293-2302.
120. Brightbill HD, Libraty DH, Krutzik SR, et al.: Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999;285:732-736.
121. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, et al.: Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci USA 2009; 106:3455-3460.